Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS
· Real-Time Price · USD
8.16
0.00 (0.00%)
At close: Jun 24, 2025, 3:59 PM
0.00% (1D)
| Bid | 5.87 |
| Market Cap | 564.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.52M |
| EPS (ttm) | -0.68 |
| PE Ratio (ttm) | -12 |
| Forward PE | -7.7 |
| Analyst | Hold |
| Ask | 10.44 |
| Volume | 8,756,394 |
| Avg. Volume (20D) | 2,158,092 |
| Open | 8.16 |
| Previous Close | 8.16 |
| Day's Range | 8.16 - 8.16 |
| 52-Week Range | 0.83 - 8.35 |
| Beta | 0.37 |
About RGLS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RGLS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RGLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+136.8%
Regulus Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
4 months ago
+16.28%
Regulus Therapeutics shares are trading higher after the company announced topline results from the phase 1b MAD study of Farabursen for autosomal dominant polycystic kidney disease.
1 month ago · https://www.marketscreener.com
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..Novartis AG (SWX:NOVN) submitted a written non-binding indication of interest to acquire Regulus Therapeutics Inc. (NasdaqCM:RGLS) for approximately $200 million on April 4, 2025. Novartis AG (SWX:NOV...